CARMEL, Ind., March 21, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today its been awarded a contract from the Sedgwick County Health Department in Kansas to train first responders and community members on substance use disorder and overdose prevention. The four-year contract underscores Syra Health's commitment to healthcare education and training.
Syra Health's comprehensive educational training program is designed for the public safety of the community. The overall objective of the training is to equip healthcare professionals, community leaders, and individuals with the knowledge and skills necessary to effectively prevent, identify, and manage substance use disorder, using evidence-based practices and innovative approaches. Specifically, Syra Health will provide ongoing, culturally relevant, educational trainings on stigma reduction surrounding substance use disorder, education on substance use disorder itself, and substance overdose prevention strategies.
According to a 2022 National Survey on Drug Use and Health, approximately 17.3% of people aged 12 or older in the United States had a substance use disorder within the past year. This includes 29.5 million individuals with an alcohol use disorder, 27.2 million with a drug use disorder, and 8.0 million people who experienced both an alcohol and drug use disorder. Among young adults aged 18 to 25, nearly 48.8% had either a substance use disorder or a mental illness during the same period.
Dr. Deepika Vuppalanchi, CEO, Syra Health, emphasized the importance of this collaboration, "This contract underscores our shared commitment to addressing this critical public health issue. It's essential to understand the prevalence of substance use disorders in the United States and the strategies that are helping improve health for those on the front line and those in community with one another."
ABOUT SYRA HEALTH
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.
FORWARD-LOOKING STATEMENTS
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Investors should read the risk factors set forth in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.94 |
Daily Change: | -0.06 -5.86 |
Daily Volume: | 138,116 |
Market Cap: | US$6.220M |
August 08, 2024 July 30, 2024 May 14, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB